drugset / Trial / NCT05253118
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
Phase 2
Active not recruiting
28 enrolled
Seoul National University Hospital
Chungnam National University Hospital · collabGyeongsang National University Hospital · collabInje University Haeundae Paik Hospital · collabKyunghee University Medical Center · collab
NaSingle-groupOpen-labelTreatment
Summary
Relapsed or refractory primary DLBCL of the CNS
Timeline
- Start
- 2022-08-18
- Primary completion
- 2026-12-28
- Completion
- 2026-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |